European Academy of Dermatology and Venereology

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

New findings confirm delgocitinib cream's safety and efficacy for chronic hand eczema, marking a significant advancement in treatment options.

In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.

New research highlights delgocitinib cream's effectiveness for treating chronic hand eczema in adolescents.

Discover how roflumilast foam transforms treatment for seborrheic dermatitis, showing effectiveness across diverse skin tones.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

New phase 2b data reveals temtokibart significantly improves atopic dermatitis symptoms in adult patients.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.